Age-related Macular Degeneration, Atrophy, Eye Diseases, Geographic Atrophy
Conditions
Keywords
Retina, Retinal pigment epithelium
Brief summary
Dry age-related macular degeneration (AMD) is a common cause for severe visual loss in the elderly and represents an unmet need. So far no treatment is available for geographic atrophy (GA), which represents the advanced dry form characterized by expanding areas of outer retinal atrophy with corresponding absolute scotoma. The foveal retina may be spared until late in the course of the disease, a phenomenon termed foveal sparing. However, the disease process ultimately also involves the central retina leading to irreversible loss of central vision. While the natural history of eyes with GA has been extensively studied with regard to the entire atrophic area, morphology-function analyses for foveal sparing GA in particular are still missing. Such data are needed for various purposes including the future use in interventional pharmacological trials aiming to slow the progression of GA and to preserve the foveal retina. In this study, different imaging modalities for accurate detection and quantification of preserved foveal retinal areas will be assessed.
Interventions
OTHERNo intervention - Natural history study
Sponsors
Genentech, Inc.
University Hospital, Bonn
Study design
Observational model
CASE_CROSSOVER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Informed consent * The study eye must have a contiguous well-demarcated area of GA either in a complete ring around the spared fovea or in a horseshoe pattern with a total atrophy size of ≤ 7 Disk Areas * Patient is willing to undergo ocular examination
Exclusion criteria
* The presence or history of CNV (choroidal neovascular membrane) in the study eye * Ocular disease in the study eye that may confound assessment of the retina, other than non-exudative AMD (e.g., diabetic retinopathy, uveitis) * Cataract surgery or ocular surgery in the study eye within 30 days prior to the baseline visit * Current or previous participation in clinical studies investigating drugs, medical devices or supplements within 30 days prior to enrolment in the study - Previous or concomitant therapy to reat AMD (investigational or FDA approved); oral supplements of vitamins and minerals are permitted * Known medical history of allergy or sensitivity to tropicamide or fluorescein dye that is clinically relevant in the investigator's opinion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity (BCVA) | baseline |
Secondary
| Measure | Time frame |
|---|---|
| Size of Geographic atrophy area as determined by confocal laser scanning ophthalmoscopy (in mm²) | baseline |
| Size of foveal sparing area as determined by confocal laser scanning ophthalmoscopy (in mm²) | baseline |
Countries
Germany
Outcome results
None listed